Verification evidence is still being completed.
PDF / print export
Elypta
Solna, Sweden
- Verified lead
- Karl Bergman
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Liquid Biopsy, Cancer Diagnostics, Metabolomics, Early Detection, and IVD Development
- Review cycle
- May 2026
- Full address
- Elypta AB, Scheeles vag 3, 171 65 Solna, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Elypta contact page confirming the Solna operating address.
- Editorial note
- Elypta is published because official company materials confirm current leadership, Solna operating address, and a clear cancer-diagnostics platform.
Liquid Biopsy, Cancer Diagnostics, Metabolomics, Early Detection, and IVD Development
Official leadership disclosure, Official Solna address disclosure, ISO 13485 disclosure
Elypta is published because official company materials confirm current leadership, Solna operating address, and a clear cancer-diagnostics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Solna, Sweden
Elypta
Liquid Biopsy, Cancer Diagnostics, Metabolomics, Early Detection, and IVD Development · Diagnostics platform
Verified 21 Mar 2026 · 2 sources
Diagnostics
Elypta runs liquid biopsy development, cancer biomarker programs, and ivd kit development in Solna, Sweden.
Contact & location
- Website
- elypta.com
- Company page
- Lead
- Karl Bergman (verified ↗)
- Compliance
- ISO 13485 disclosure
- Last reviewed
- 21 Mar 2026 (3mo ago)
- Scale
- Diagnostics platform
- Capabilities
- Liquid Biopsy Development · Cancer Biomarker Programs · IVD Kit Development
- Founded
- 2017
- Headcount
- 11-50
Clinical profileSTATUS: VERIFIED MARCH 2026
Karl Bergman
CEO
Full addressElypta AB, Scheeles vag 3, 171 65 Solna, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Diagnostics platform
Solna, Sweden. Liquid Biopsy, Cancer Diagnostics, Metabolomics, Early Detection, and IVD Development. Review completed on 21 Mar 2026.
Swedish diagnostics and medical-device oversight
Official leadership disclosure, Official Solna address disclosure, ISO 13485 disclosure
Liquid Biopsy, Cancer Diagnostics, Metabolomics, Early Detection, and IVD Development
Elypta is published because official company materials confirm current leadership, Solna operating address, and a clear cancer-diagnostics platform.
Editorial note
Elypta is published because official company materials confirm current leadership, Solna operating address, and a clear cancer-diagnostics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Liquid Biopsy Development
Cancer Biomarker Programs
IVD Kit Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Biomarker-analysis workflow
IVD development systems
Machine-learning diagnostics workflow
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- VERIFIED ACTIVE 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Elypta located?
- Elypta operates from Elypta AB, Scheeles vag 3, 171 65 Solna, Sweden, Solna, Sweden.
- Who runs Elypta?
- Elypta is led by Karl Bergman, CEO. Verified 21 Mar 2026.
- What certifications does Elypta hold?
- Elypta is documented under ISO 13485 disclosure.
- What does Elypta do?
- Elypta runs liquid biopsy development, cancer biomarker programs, and ivd kit development in Solna, Sweden. Core capabilities: Liquid Biopsy Development, Cancer Biomarker Programs, IVD Kit Development.
Editorial context
Related technical briefs
Briefs that name Solna as a covered market or city.